2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Monoclonal Antibody Therapy, Non-Biological Therapies, Anticoagulant Drugs, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Generative AI, Machine Learning, Natural Language Processing, Biological Processes, Apoptosis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Diseases, Bleeding and Clotting, Bleeding Disorders, Platelet Disorders, Thromboembolism, Thrombotic Disorders, VWD, Genetic Disorders, Immunology, Autoimmune Disorders, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

5559 GLP-1 receptor agonist use in polycythemia vera: Association with thrombosis and survival after accounting for immortal time bias

Lauren Fang, MD, Amina Akram, MBBS2, Buraq Ahmed3, Animesh Pardanani, PhD, MBBS4, Ayalew Tefferi, MD5, Naseema Gangat, MBBS6
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, United States
3 University of Cambridge, Cambridge, United Kingdom
4 Mayo Clinic, Rochester, United States
5 Mayo Clinic, Rochester, United States
6 Mayo Clinic, Rochester, United States

Background
Polycythemia vera (PV) carries an increased risk of arterial and venous thrombosis. GLP-1 receptor agonists (GLP-1RA), increasingly prescribed for type 2 diabetes mellitus and obesity, promote weight loss and have anti-inflammatory and cardioprotective effects. This has prompted interest in GLP-1RA in myeloproliferative neoplasms (MPN), where preliminary registry analyses suggest more favorable outcomes in exposed patients (Chang et al., ISTH 2025; Cheema et al., Clin Lymphoma Myeloma Leuk 2025). However, such observations are susceptible to immortal time bias, in which longer-surviving patients are preferentially classified as exposed. We assessed the association of GLP-1RA exposure with overall survival (OS) and incidence of arterial and venous thrombosis in PV, using methods accounting for immortal time bias.

Methods
Within a Mayo Clinic PV cohort, GLP-1RA recipients were compared with non-recipients. OS was estimated by Kaplan-Meier analysis and Cox regression treating GLP-1RA exposure as a time-dependent covariate. Analyses were adjusted for age, sex, diabetes, prior thrombosis, and revised International Working Group (IWG) risk. Among recipients, thrombotic events were divided into pre-exposure, active exposure, and post-discontinuation periods. Incidence rates (events per 100 person-years) and incidence rate ratios (IRRs; exact Poisson tests) were compared between exposure periods and with non-recipients.

Results
Comparison of GLP-1RA users and non-users. Among 1,060 patients with PV, 93 (9%) received GLP-1RA, initiated a median of 59 months (range, -73 to 390) relative to PV diagnosis for a median of 23 months (range, 0-87). Semaglutide (59%) and tirzepatide (55%) were the most commonly prescribed GLP-1RAs. Compared with non-users, recipients were younger (median age, 56 vs 62 years; p<0.001) and more often had diabetes (49% vs 12%; p<0.001), hypertension (71% vs 53%; p<0.001), and a smoking history (35% vs 10%; p<0.001), with lower hemoglobin (15.5 vs 17.4 g/dL; p<0.001) and leukocytes (9.5 vs 10.8 x10^9/L; p=0.007). Sex (female, 51% vs 49%; p=0.84) and prior arterial (13% vs 14%) and venous (15% vs 14%) thrombosis were comparable. Recipients were less often high/very-high risk by the revised IWG survival model (16% vs 46%; p<0.001), a difference driven by younger age, with similar within-strata distributions. Aspirin (92% vs 94%) and cytoreductive therapy (85% vs 90%; p=0.18) exposure were similar.

Overall survival. After a median follow-up of 9.6 years, 1 (1%) recipient and 436 (45%) non-recipients had died. Without accounting for immortal time bias, GLP-1RA use was associated with superior OS (p<0.001), persisting after adjustment for age and sex (p=0.007), diabetes (p=0.004), and revised IWG risk (p=0.004). However, after modeling GLP-1RA as a time-dependent covariate, this association was markedly attenuated (p=0.046) and non-significant after multivariable adjustment (p=0.14-0.21), including among diabetics (p=0.28).

Arterial and Venous Thrombosis. During post-diagnosis follow-up, recipients experienced 15 arterial and 17 venous thrombotic events (152 and 153, respectively, among non-recipients). Among recipients, 24 events (11 arterial/13 venous) occurred before GLP-1RA initiation (662.0 person-years; 3.63 per 100 person-years), 4 (2 arterial/2 venous) during active exposure (126.4 person-years; 3.16 per 100 person-years), and 4 (2 arterial/2 venous) after discontinuation (41.1 person-years; 9.7 per 100 person-years). Non-recipients experienced 305 thrombotic events during 11,230 person-years of follow-up (2.7 per 100 person-years). The incidence rate during GLP-1RA exposure was similar to the pre-exposure period (IRR 0.87; 95% CI 0.22-2.54; p=1.00) and comparable to the rate in non-recipients (3.16 vs 2.72 per 100 person-years; IRR 1.17; 95% CI 0.32-3.01; p=0.59).

Conclusion
In PV, the apparent survival advantage of GLP-1RA therapy was fully explained by immortal time bias, with no independent survival benefit after time-dependent modeling. Thrombotic event rates during GLP-1RA exposure did not differ significantly from the recipients' pre-exposure period or from non-recipients. These findings should be interpreted cautiously given the limited number of on-treatment events and potential confounding by indication, as GLP-1RA recipients had a higher burden of diabetes and other cardiovascular risk factors than non-recipients.

Lauren Fang, MD: No relevant conflicts of interest to declare.